Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 6 |
| List of Tables | 5 | 2 |
| List of Figures | 7 | 2 |
| Orphan Diseases Therapeutics in CNS - Introduction | 9 | 2 |
| GBI Research Report Guidance | 10 | 1 |
| Orphan Diseases Therapeutics in CNS - Market Overview | 11 | 12 |
| Introduction | 11 | 1 |
| Orphan Disease Regulation and Incentives | 11 | 2 |
| Global Revenue Forecasts for Orphan Diseases Therapeutics in CNS | 13 | 1 |
| Global Revenue and Forecast | 13 | 2 |
| Geographical Segmentation | 15 | 2 |
| Branded and Generic Market Share | 17 | 1 |
| Revenue Share by Indication | 18 | 2 |
| Market Drivers | 20 | 1 |
| Regulatory Incentives will Encourage R&D | 20 | 1 |
| Targeting Non-Orphan Indications with Orphan Drugs Increases Market Potential for Orphan Drugs | 20 | 1 |
| Generic Drugs are not a Threat to Disease-Modifying Therapies | 21 | 1 |
| Market Restraints | 21 | 1 |
| Conducting Clinical Trials for Orphan Diseases in the CNS is Difficult | 21 | 1 |
| CNS Diseases are Poorly Understood and this Hinders Drug Development | 21 | 1 |
| Unmet Needs | 21 | 1 |
| Opportunities | 22 | 1 |
| Orphan Diseases Therapeutics in CNS - Geographical Landscape | 23 | 4 |
| The US | 23 | 1 |
| Revenue | 23 | 2 |
| Top Five Countries of Europe | 25 | 1 |
| Revenue | 25 | 1 |
| Japan | 26 | 1 |
| Revenue | 26 | 1 |
| Orphan Diseases in CNS Disorders - Therapeutic Landscape | 27 | 44 |
| Amyotrophic Lateral Sclerosis | 27 | 1 |
| Disease Overview | 27 | 1 |
| Revenue | 27 | 4 |
| Average Annual Cost of Treatment | 31 | 2 |
| Branded and Generic Market Share | 33 | 1 |
| Treatment Algorithm | 34 | 1 |
| Treatment Usage Patterns | 34 | 1 |
| Diseased Population | 34 | 2 |
| Treatment Seeking Population | 36 | 2 |
| Diagnosed Population | 38 | 2 |
| Prescription Population | 40 | 1 |
| Approved Molecules | 41 | 1 |
| Rilutek | 41 | 1 |
| Mechanism of Action | 41 | 1 |
| Efficacy Details | 41 | 1 |
| Safety Profile | 41 | 1 |
| Cost of Therapy | 42 | 1 |
| Nuedexta (Dextromethorphan Hydrobromide and Quinidine Sulfate) | 42 | 1 |
| Mechanism of Action | 42 | 1 |
| Efficacy | 42 | 1 |
| Safety | 42 | 1 |
| Cost of Therapy | 43 | 1 |
| Huntington s Disease | 43 | 1 |
| Disease Overview | 43 | 1 |
| Total Revenue | 44 | 3 |
| Average Annual Cost of Treatment (ACT) | 47 | 1 |
| Branded and Generic Market Share | 48 | 1 |
| Treatment Algorithm | 49 | 1 |
| Treatment Usage Patterns | 50 | 1 |
| Diseased Population | 50 | 1 |
| Treatment Seeking Population | 51 | 1 |
| Diagnosed Population | 52 | 1 |
| Prescription Population | 53 | 1 |
| Approved Molecules | 54 | 1 |
| Xenazine (tetrabenazine) | 54 | 1 |
| Mechanism of Action | 54 | 1 |
| Efficacy Details | 54 | 1 |
| Safety Profile | 54 | 1 |
| Cost of Therapy | 55 | 1 |
| Myasthenia Gravis | 55 | 1 |
| Disease Overview | 55 | 1 |
| Total Revenue | 56 | 3 |
| Branded and Generic Market Share | 59 | 1 |
| Average Annual Cost of Treatment | 60 | 1 |
| Treatment Algorithm | 61 | 1 |
| Treatment Usage Patterns | 62 | 1 |
| Diseased Population | 62 | 1 |
| Treatment Seeking Population | 63 | 1 |
| Diagnosed Population | 64 | 1 |
| Prescription Population | 65 | 1 |
| Approved Molecules | 66 | 1 |
| Prograf (Tacrolimus) | 66 | 1 |
| Other Indications | 67 | 1 |
| Total Revenue | 67 | 1 |
| Product Profiles | 68 | 1 |
| Apokyn (Apomorphine Hydrochloride) | 68 | 1 |
| Diacomit (Stiripentol) | 68 | 1 |
| Banzel (Rufinamide) | 69 | 1 |
| Lamictal (Lamotrigine) | 69 | 1 |
| Modafinil | 70 | 1 |
| Prialt (Ziconotide Intrathecal Infusion) | 70 | 1 |
| Global Orphan Diseases in CNS Disorders - Pipeline Analysis | 71 | 14 |
| Introduction | 71 | 1 |
| Research and Development Pipeline | 72 | 1 |
| Overview | 72 | 3 |
| Pipeline by Clinical Phases of Development | 75 | 1 |
| Discovery | 75 | 1 |
| Pre-clinical | 76 | 2 |
| IND Filed | 78 | 1 |
| Phase I | 79 | 1 |
| Phase II | 80 | 1 |
| Phase III | 81 | 1 |
| Profiles of Promising Drugs in Orphan Diseases in CNS Disorders | 82 | 1 |
| CK-2017357 | 82 | 1 |
| Dexpramipexole | 82 | 1 |
| NP001 | 82 | 1 |
| TRO19622 (Olesoxime) | 82 | 1 |
| Huntexil | 83 | 1 |
| AMR 101 | 83 | 1 |
| HD-02 | 83 | 1 |
| SEN196 | 83 | 1 |
| Venoglobulin-IH | 83 | 1 |
| Revimmune | 84 | 1 |
| Soliris (Eculizumab) | 84 | 1 |
| Global Orphan Diseases in CNS Disorders - Competitive Landscape | 85 | 10 |
| Major Players | 85 | 1 |
| Major Company Profiles | 85 | 1 |
| Biogen Idec | 85 | 1 |
| SWOT Analysis | 85 | 1 |
| Avanir | 86 | 1 |
| SWOT Analysis | 86 | 1 |
| Neuraltus | 87 | 1 |
| SWOT Analysis | 87 | 1 |
| Cytokinetics | 88 | 1 |
| SWOT Analysis | 88 | 1 |
| Avicena | 89 | 1 |
| SWOT Analysis | 89 | 1 |
| NeuroSearch | 90 | 1 |
| SWOT Analysis | 90 | 1 |
| Trophos | 91 | 1 |
| SWOT Analysis | 91 | 1 |
| Amarin | 92 | 1 |
| SWOT Analysis | 92 | 1 |
| Siena Biotech | 93 | 1 |
| SWOT Analysis | 93 | 1 |
| Sanofi | 94 | 1 |
| SWOT Analysis | 94 | 1 |
| Global Orphan Diseases in CNS Disorders - Strategic Consolidations | 95 | 21 |
| Mergers and Acquisitions | 95 | 1 |
| Overview | 95 | 2 |
| Major Mergers and Acquisitions Deals | 97 | 1 |
| H. Lundbeck Acquires LifeHealth | 97 | 1 |
| H. Lundbeck Acquires OVATION Pharmaceuticals | 97 | 1 |
| CytRx Acquires Clinical and Pharmaceutical Assets from Biorex | 97 | 1 |
| Pfizer Acquires FoldRx Pharmaceuticals | 97 | 1 |
| Segmentation by Indication | 98 | 1 |
| Segmentation by Geography | 99 | 1 |
| Segmentation by Deal Value | 100 | 1 |
| Segmentation by Year | 101 | 1 |
| Licensing Agreements | 102 | 1 |
| Overview | 102 | 3 |
| Major Licensing Deals | 105 | 1 |
| NeuroSearch Terminates Licensing Agreement with Astellas Pharma for the Rights for ACR16 | 105 | 1 |
| Biovail Acquires Rights for Tetrabenazine and Related Assets from Cambridge Laboratories | 105 | 1 |
| Biogen Idec Enters into Licensing Agreement with Knopp Neurosciences for KNS-760704 | 106 | 1 |
| Brain Science Institute Enters into Licensing Agreement with Eisai | 106 | 1 |
| Debiopharm Enters into Licensing Agreement with DeveloGen | 106 | 1 |
| Amorfix Life Sciences Enters into Licensing Agreement with Biogen Idec | 106 | 1 |
| Segmentation by Indication | 107 | 1 |
| Segmentation by Geography | 108 | 1 |
| Segmentation by Deal Value | 109 | 1 |
| Segmentation by Year | 110 | 1 |
| Co Development Deals | 111 | 2 |
| Segmentation by Geography | 113 | 1 |
| Segmentation by Value | 114 | 1 |
| Segmentation by Year | 115 | 1 |
| CNS Orphan Diseases - Appendix | 116 | 9 |
| Market Definition | 116 | 1 |
| Abbreviations | 116 | 1 |
| Research Methodology | 117 | 2 |
| Coverage | 118 | 1 |
| Secondary Research | 118 | 1 |
| Primary Research | 118 | 1 |
| Forecasting | 119 | 2 |
| Epidemiology-based Forecasting | 119 | 1 |
| Expert Panels Validation | 120 | 1 |
| Contact Us | 120 | 1 |
| Disclaimer | 120 | 1 |
| Sources | 120 | 5 |